Who are Barhemsys's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pramipexole (Mirapex), LYBALVI, Aripiprazole Augmentation, Quetiapine and Topiramate, Adjunctive asenapine, Asenapine - Double Blind.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amisulpride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Barhemsys — Competitive Intelligence Brief

Barhemsys (AMISULPRIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine-2 Receptor Antagonist [EPC]. Area: Neuroscience.

marketed Dopamine-2 Receptor Antagonist [EPC] D(2) dopamine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Barhemsys (AMISULPRIDE) — Acacia. Barhemsys works by blocking dopamine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Barhemsys TARGET	AMISULPRIDE	Acacia	marketed	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	2020-01-01
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Aripiprazole Augmentation	Aripiprazole Augmentation	Centre for Addiction and Mental Health	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Adjunctive asenapine	Adjunctive asenapine	Lori Davis, MD	marketed	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor
Asenapine - Double Blind	Asenapine - Double Blind	Organon and Co	phase 3	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine-2 Receptor Antagonist [EPC] class)

Acacia · 1 drug in this class
Rising · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Barhemsys — Competitive Intelligence Brief. https://druglandscape.com/ci/amisulpride. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab